Navigation Links
ATS Medical Announces Second Quarter 2009 Results

MINNEAPOLIS, Aug. 3 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported financial results for its second quarter ended July 4, 2009.


Second Quarter 2009 Results

Revenue for the quarter was $19.8 million, or 17.0% higher than the second quarter of 2008. Revenue from the Company's heart valve therapy products, consisting of mechanical valves, tissue valves and repair products, was up 21.9% on a year-over-year basis to $14.7 million. Revenue from the Company's ATS CryoMaze(TM) cryoablation products for the treatment of cardiac arrhythmias was $4.7 million, an increase of 7.7% compared to the second quarter of 2008. Excluding the impact of foreign currency fluctuations revenue growth for the quarter was 21.7% overall, 27.6% for heart valve therapy products and 10.0% for cryoablation products.

Gross profit margin for the second quarter of 2009 was 64.4%, representing significant improvement from 60.9% in the second quarter of 2008. Year-over-year gross margin improvements were primarily the result of lower mechanical valve and CryoMaze product costs resulting from increased production.

Operating income for the second quarter of 2009 was $0.2 million compared with an operating loss of $2.8 million in the second quarter of 2008. The GAAP net loss for the second quarter of 2009 was $0.2 million, or $0.00 per share, compared with $4.7 million, or $0.08 per share, in the second quarter of 2008.

The Company also had non-GAAP earnings before interest, taxes, depreciation and amortization (EBITDA) in the second quarter of 2009 of $1.9 million compared to an EBITDA loss of $2.4 million in the second quarter of 2008. A reconciliation of reported net loss to non-GAAP EBITDA for these periods is provided in a schedule accompanying this press release.

"We are very pleased with our income statement performance in the second quarter as we achieved positive operating income and reduced our net loss to almost breakeven," said Michael Dale, President and Chief Executive Officer. "Our revenue growth coupled with increased operating discipline is yielding operating leverage and positioning us to achieve our goal of positive net income in the next few quarters."

Product Highlights

Mechanical Heart Valves

  • Mechanical valve revenue was $11.9 million in the second quarter of 2009, an increase of 10% over the second quarter of 2008.
  • The Company and its Japanese distribution partner, Century Medical, commenced distribution of the AP360 mechanical valve in Japan during the quarter.

Tissue Heart Valves

  • Tissue valve revenue during the second quarter of 2009 was $1.6 million compared to $0.5 million in the comparable quarter of 2008 and $1.1 million in the first quarter of 2009. U.S. revenue represented more than 50% of total tissue valve revenue in the second quarter.
  • Professor Joerg Linneweber from Charite-Universitatsmedizin Berlin presented five-year single center follow-up data on the ATS 3F Aortic Bioprosthesis highlighting the valve's excellent safety and performance profile.
  • Dr. Xu Yu Jin of the John Radcliffe Hospital, Oxford, U.K. presented five-year hemodynamic performance data on the ATS 3F Aortic Bioprosthesis as assessed by valve energy loss and pressure gradient. Dr. Jin's findings support a significant hemodynamic advantage with the ATS 3f valve.
  • In July 2009, the Company submitted the clinical module of its CE Mark submission for the ATS 3F Enable sutureless tissue valve designed to enable minimally invasive aortic valve replacement. The Company expects CE Mark approval in the second half of 2009.

Heart Valve Repair

  • Heart valve repair revenue in the second quarter of 2009 was $1.2 million, an increase of 54% compared to the second quarter of 2008.
  • The Company received regulatory approval of the Simulus semi-rigid band in the second quarter. The semi-rigid band expands the Company's annuloplasty repair product portfolio to meet broader clinical applications. The Company plans to launch at least one additional repair product in the second half of 2009.

Surgical Ablation

  • Cryoablation revenues of $4.7 million in the second quarter of 2009 increased 8% over second quarter of 2008.
  • In July 2009, the Company announced the first use of the new CryoMaze(TM) 10-S Surgical Cryoablation Probe, which offers increased support throughout the length of the ablation segment. The increased rigidity of the probe addresses the preference of some surgeons to have a cryoablation probe with the feel of a more substantial surgical instrument. The ATS CryoMaze 10-S Probe has optimal shape retention while remaining distinctly malleable by hand. This combination of attributes makes the probe particularly useful in minimally invasive cardiac arrhythmia procedures.
  • Full release of the ATS CryoMaze 10-S Probe in the U.S. will be in August, 2009.

"We continue to be encouraged by the performance of our new product introductions and progress within our R&D pipeline," commented Mr. Dale. "Looking ahead over the next twelve months we expect to continue the expansion of our market positions in heart valve therapy and surgical ablation through the introduction of genuinely differentiated product solutions."

2009 Guidance

For the full year 2009 the Company revised its previous revenue guidance of $77 to $80 million to $77 to $79 million. The adjustment to revenue guidance is primarily related to the termination of the Company's distribution contract for an anastomotic assist product the Company has distributed since October 2006. Additionally, the Company continues to expect to generate an operating profit on an annual basis and net income in the fourth quarter of 2009.

Conference Call Today

ATS management will host a conference call today, August 3, 2009, at 5:00 p.m. ET to discuss its 2009 second quarter financial results and current corporate developments. The dial-in number for the conference call is 866-700-7477 for domestic participants and 617-213-8840 for international participants with a passcode of 94675879. A live webcast of the call can also be accessed at by clicking on the Investors icon.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 888-286-8010 for domestic participants and 617-801-6888 for international callers, using the passcode 99143264.

Disclosure of Non-GAAP Financial Measures

ATS reports its financial results in accordance with generally accepted accounting principles ("GAAP"). In addition, from time to time, we include other measures in our releases which are not prepared in accordance with GAAP. Investors should consider these non-GAAP financial measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. Non-GAAP financial measures used by ATS may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. In this release we have included disclosures of earnings before interest, taxes, depreciation and amortization (EBITDA), a non-GAAP financial measure, for the second quarter and first half of 2009 and 2008. We use EBITDA in our internal analysis and review of our operational performance. We believe that this non-GAAP measure provides investors with useful information in comparing our operational performance over different periods. By using this non-GAAP measure we believe investors get a better picture of the performance of our underlying business. We have also included as an attachment to this release a schedule which reconciles net loss reported in accordance with GAAP to the EBITDA amounts presented above.

About ATS Medical

ATS Medical, Inc. is dedicated to "Advancing The Standards" of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) heart valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive, sutureless procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2008 and its most recent quarterly report on Form 10-Q.

    ATS Medical, Inc.
    Condensed Consolidated Statements
     of Operations
    (in thousands except per share amounts)

                                         Quarter Ended     Six Months Ended
                                          -------------    ----------------
                                         July 4, June 28,  July 4,  June 28,
                                          2009     2008     2009     2008
                                          ----     ----     ----     ----

    Net sales                           $19,781  $16,900  $38,184  $31,745
    Cost of goods sold                    7,040    6,610   13,170   12,507
                                          -----    -----   ------   ------
    Gross profit                         12,741   10,290   25,014   19,238

    Operating expenses:
          Sales and marketing             7,525    7,147   15,026   13,634
          Research and development        1,817    2,302    3,861    4,508
          General and administrative      2,431    2,764    4,907    5,768
          Amortization of intangibles       812      890    1,600    1,781
                                            ---      ---    -----    -----
               Total operating expenses  12,585   13,103   25,394   25,691
                                         ------   ------   ------   ------
    Operating income (loss)                 156   (2,813)    (380)  (6,453)

    Interest expense, net                  (694)    (657)  (1,413)  (1,276)
    Other income (expense), net             471   (1,040)     118      878
                                            ---  -------      ---      ---

    Net loss before income taxes            (67)  (4,510)  (1,675)  (6,851)
    Income tax expense                     (119)    (159)    (182)    (229)
                                          -----    -----    -----    -----

    Net loss                              ($186) ($4,669) ($1,857) ($7,080)
                                          =====  =======  =======  =======

    Net  loss per share:
       Basic and diluted                 ($0.00)  ($0.08)  ($0.03)  ($0.12)
                                        =======  =======  =======  =======

    Weighted average number of shares
       Basic and diluted                 71,688   60,018   71,471   59,877
                                         ======   ======   ======   ======

    ATS Medical, Inc.
    Condensed Consolidated Balance Sheets
    (in thousands)

                                                   July 4,       December 31,
                                                    2009             2008
                                                    ----             ----
    Cash and short-term investments               $11,322          $20,895
    Accounts receivable                            15,343           14,532
    Inventories, net                               21,227           20,208
    Prepaid expenses                                1,746              958
                                                    -----              ---
        Total current assets                       49,638           56,593

    Property and equipment, net                     6,792            7,031
    Intangible assets                              47,530           49,131
    Other assets                                    1,455            2,226
                                                    -----            -----
    Total assets                                 $105,415         $114,981
                                                 ========         ========

    Liabilities & shareholders' equity
    Accounts payable                               $4,233           $4,054
    Accrued compensation                            2,001            3,537
    Current maturities of bank notes
     payable                                        2,646            2,646
    Payable to CryoCath Technologies Inc.               -            1,910
    Payable to CarboMedics Inc.                         -            4,500
    Other accrued liabilities                       2,319            2,257
                                                    -----            -----
        Total current liabilities                  11,199           18,904

    Convertible senior notes payable               17,593           17,533
    Bank notes payable                              2,426            3,969

    Shareholders' equity                           74,197           74,575
                                                   ------           ------
    Total liabilities & shareholders'
     equity                                      $105,415         $114,981
                                                 ========         ========

    ATS Medical, Inc.
    Consolidated Condensed Statements of Cash Flow
    (in thousands)

                                                        Six Months Ended
                                                    July 4,           June 28,
                                                     2009               2008
                                                     ----               ----
    Operating activities
    Net loss                                      ($1,857)           ($7,080)
    Adjustments to reconcile net loss
     to net cash
           used in operating activities:
        Depreciation and amortization               2,540              2,946
        Stock-based compensation expense            1,197                769
        Deferred income taxes                         141                 96
        Non-cash interest expense                     431                317
        Change in value of warrant
         liability and derivative liability           (18)              (273)
            bifurcated from convertible senior
        Changes in operating assets and
         liabilities                               (8,442)            (1,278)
                                                  -------            -------
    Net cash used in operating
     activities                                    (6,008)            (4,503)

    Investing activities
        Maturities of short-term
         investments, net of purchases                  -              4,183
        Payments for business acquisitions         (2,000)            (1,000)
        Purchases of furniture, machinery
         and equipment                               (699)              (886)
                                                    -----              -----
    Net cash provided by (used in)
     investing activities                          (2,699)             2,297

    Financing activities
        Payments on notes payable                  (1,543)              (662)
        Net proceeds from issuance of
         common stock                                 158              3,381
        Other                                         508                 31
                                                      ---                 --
        Net cash provided by (used in)
         financing activities                        (877)             2,750

    Effect of foreign exchange rate
     changes                                           11               (117)
                                                       --              -----
    Increase (decrease) in cash and
     cash equivalents                             ($9,573)              $427
                                                 ========               ====

    ATS Medical, Inc.
    Selected Revenue Information
    (in thousands)

                           Quarter Ended      Six Months Ended
                           -------------      ----------------
                          July 4,  June 28,   July 4,   June 28,
                           2009      2008      2009      2008
                           ----      ----      ----      ----

    Heart valve therapy  $14,736   $12,093   $27,981   $22,774
    Surgical arrhythmia    4,722     4,386     9,626     8,234
    Surgical tools &
     accessories             323       421       577       737
                             ---       ---       ---       ---

      Total revenue      $19,781   $16,900   $38,184   $31,745
                         =======   =======   =======   =======

    ATS Medical, Inc.
    Reconciliation of GAAP
     Net Loss to Non-GAAP
    (Unaudited, in thousands)
                                    Quarter Ended        Six Months Ended
                                    -------------        ----------------
                                  July 4,    June 28,  July 4,   June 28,
                                   2009        2008     2009      2008
                                   ----        ----     ----      ----

    Net loss, as reported         $(186)     $(4,669) $(1,857)  $(7,080)
    Adjustments to net loss:
        Interest expense            709          708    1,433     1,421
        Income tax  expense         119          159      182       229
        Depreciation                474          560      940     1,165
        Amortization                812          890    1,600     1,781
                                    ---          ---    -----     -----

    Earnings (loss) before
     interest, taxes,
        depreciation and
         amortization            $1,928      $(2,352)  $2,297   $(2,484)
        (EBITDA)                 ======     ========   ======  ========

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Greenway Medical Technologies EHR Solution, PrimeSuite, Enables Eligible Professionals to Participate in PQRI Through Integration With Outcome Sciences, a 2009 CMS Qualified PQRI Registry
2. RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System
3. New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care
4. Cantel Medicals Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment
5. Medical Services of America Selects Authentidates Inscrybe Healthcare to Standardize Healthcare Order Process Management
6. Locum Leaders Taps Hospitalist as Chief Medical Officer; Strengthens Leadership in Hospital Medicine Recruitment and Job Placement
7. Brand New Conference on Developing 21st Century Military Medical Capabilities to be Held in Abu Dhabi
8. Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
9. Hitachi Medical Systems and Monarch Medical Announced as Co- Title Sponsors of the Health Connect Partners 2009 Fall Radiology and Imaging Conference
10. Solta Medical Reports Strong Second Quarter 2009 Results
11. Rochester Medical Reports Third Quarter Results
Post Your Comments:
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, ... FDA has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls ... meet the device regulations. , Come up short in an inspection and the FDA ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... In response ... growing epidemic as deaths from prescription opioids in the United States grew 400 percent ... In 2013 alone, opioids were involved in 37 percent of all fatal drug overdoses. ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the ... capability and technology platform company serving the pharmaceutical, biotechnology, ... China and the United States ... meeting of shareholders held today, the Company,s shareholders voted ... the previously announced agreement and plan of merger (the ...
(Date:11/24/2015)... , Nov. 24, 2015  In the pharmaceutical ... in an effort to quickly uncover new insights, tactics ... --> --> However, organizations ... market research project and ensure that all rules and ... industry standards. Another major barrier to efficiently launching market ...
(Date:11/24/2015)... Nov. 24, 2015  DILON Diagnostics and GE Healthcare ... agreement for DILON to distribute GE,s Discovery NM750b Molecular ... signing of this distribution agreement will provide Dilon,s experienced ... Imaging system and is considered an initial step in ... solutions for clinicians and their patients. ...
Breaking Medicine Technology: